News from shionogi inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 02, 2015, 08:03 ET
Shionogi Inc. Logo

Shionogi Inc. Initiates Phase 3 Clinical Study Of Osphena® For The Treatment Of Postmenopausal Vaginal Dryness

 Shionogi Inc. announced today the company has initiated a Phase 3 clinical trial to evaluate the safety and efficacy of Osphena®...

Sep 08, 2015, 14:31 ET
Shionogi Inc. Logo

New Shionogi Inc. Advertising Campaign Features A Personal Story About Painful Sex After Menopause

 There are many women in the U.S. who experience moderate to severe painful sex due to menopause, and very few are discussing it with their...

Aug 03, 2015, 08:03 ET
Shionogi Inc. Logo

Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation

Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of...

May 19, 2015, 09:34 ET
Shionogi Inc. Logo

Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation

 Shionogi Inc. today announced data from a Phase IIb study that showed 0.2 mg and 0.4 mg of naldemedine demonstrated statistically significant...

Mar 30, 2015, 02:00 ET
Shionogi & Co., Ltd. logo

Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation

 Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met...

Oct 09, 2014, 14:00 ET

Novel Siderophore Cephalosporin S-649266 Pre-Clinical Results Suggest Potent Activity Against Multidrug-Resistant Gram-Negative Pathogens

S-649266, an investigational parenteral siderophore cephalosporin, exhibits marked potency against Gram-negative bacteria, including...

Oct 01, 2014, 09:00 ET
Shionogi Inc. Logo (PRNewsFoto/Shionogi Inc.)

Shionogi Inc. Announces Four Abstracts To Be Presented At The 25th Annual Meeting Of The North American Menopause Society (NAMS) In Washington, DC

Shionogi Inc., a global leader dedicated to women's health, will unveil four abstracts containing new analyses and safety and efficacy data from...

Sep 08, 2014, 11:42 ET

Shionogi Presents Pre-Clinical and Phase I Results For S-649266, A Novel Siderophore Cephalosporine Antibiotic With Potential To Treat Multidrug-Resistant Gram-Negative Pathogens

 Findings reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) showed Shionogi's novel parenteral...

Sep 04, 2014, 09:00 ET
Shionogi Inc. Pledges to "Take Charge" in Honor of Menopause Awareness Month. Visit Today & Take The Pledge! (PRNewsFoto/Shionogi Inc.)

Shionogi Inc. Pledges to "Take Charge" in Honor of Menopause Awareness Month

This September, Shionogi Inc. supports the Women's Health Foundation with a five dollar donation for every pledge taken on

Jul 03, 2014, 09:00 ET

It's Time to Talk about Sex After Menopause, A New Campaign To Free Women From The Silence Around An Often-Neglected Area Of Women's Health

 Beginning July 4th, women, men and health care providers are encouraged to lend their social voices to an often-neglected area of women's...

Jan 13, 2014, 09:00 ET

Shionogi Inc. Announces Co-Promotion Agreement with Noven Pharmaceuticals For Brisdelle™ (Paroxetine) Capsules

 Shionogi Inc. today announced that it has entered into an exclusive, multi-year agreement with Noven Pharmaceuticals to co-promote...

Jun 25, 2013, 06:30 ET

Actress Virginia Madsen Partners With Shionogi Inc. To Empower Postmenopausal Women To Break The Silence Around Painful Intercourse Due To Menopause

Academy Award-nominated actress Virginia Madsen is never one to shy away from a conversation, even if the topic at first blush seems awkward or...

May 16, 2013, 11:03 ET

New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy

 A new survey of more than 3,000 postmenopausal women reveals that women living with vulvar and vaginal atrophy (VVA) are either unaware of...

Feb 26, 2013, 15:10 ET

Shionogi Receives FDA Approval For Osphena™ (Ospemifene) For The Treatment Of Dyspareunia, A Symptom Of Vulvar And Vaginal Atrophy (VVA), Due To Menopause

 Shionogi Inc., the United States (U.S.)-based company of Shionogi & Co., Ltd., today announced that the U.S. Food and Drug Administration...

Jul 26, 2012, 16:30 ET

Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naive Adults with HIV-1

Shionogi-ViiV Healthcare LLC today announced 48-week data from the SPRING-2 Phase III study, which is evaluating the investigational integrase...

Jul 11, 2012, 02:08 ET

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the...

Apr 02, 2012, 02:09 ET

Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV

 ViiV Healthcare and Shionogi & Co., Ltd. today announced that initial results have been received from the SPRING-2 (ING113086) Phase III...

Jan 25, 2012, 08:00 ET

Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions

 Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced results from two studies published online today in...

Aug 04, 2011, 08:00 ET

Head Lice Returns to School: Five Tips to Avoid Panic and Worry

It's back-to-school season and for many families, that means new morning routines, homework and head lice. To view the multimedia assets...

May 09, 2011, 08:00 ET